DK0457514T3 - Fremgangsmåde til forebyggelse, stabilisering eller fremkaldelse af tilbagegang af atherosklerose ved anvendelse af en kombination af et cholesterolsænkende medikament og en ACE-hæmmer - Google Patents

Fremgangsmåde til forebyggelse, stabilisering eller fremkaldelse af tilbagegang af atherosklerose ved anvendelse af en kombination af et cholesterolsænkende medikament og en ACE-hæmmer

Info

Publication number
DK0457514T3
DK0457514T3 DK91304232.1T DK91304232T DK0457514T3 DK 0457514 T3 DK0457514 T3 DK 0457514T3 DK 91304232 T DK91304232 T DK 91304232T DK 0457514 T3 DK0457514 T3 DK 0457514T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
combination
cholesterol
ace inhibitor
recurrence
Prior art date
Application number
DK91304232.1T
Other languages
English (en)
Inventor
Werner Tschollar
James L Bergey
James C Kawano
Cary S Yonce
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of DK0457514T3 publication Critical patent/DK0457514T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91304232.1T 1990-05-15 1991-05-10 Fremgangsmåde til forebyggelse, stabilisering eller fremkaldelse af tilbagegang af atherosklerose ved anvendelse af en kombination af et cholesterolsænkende medikament og en ACE-hæmmer DK0457514T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52426690A 1990-05-15 1990-05-15

Publications (1)

Publication Number Publication Date
DK0457514T3 true DK0457514T3 (da) 1996-09-16

Family

ID=24088484

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91304232.1T DK0457514T3 (da) 1990-05-15 1991-05-10 Fremgangsmåde til forebyggelse, stabilisering eller fremkaldelse af tilbagegang af atherosklerose ved anvendelse af en kombination af et cholesterolsænkende medikament og en ACE-hæmmer

Country Status (15)

Country Link
EP (1) EP0457514B1 (da)
JP (1) JPH04226921A (da)
KR (1) KR100200467B1 (da)
AT (1) ATE141514T1 (da)
AU (1) AU651579B2 (da)
CA (1) CA2040865C (da)
DE (1) DE69121464T2 (da)
DK (1) DK0457514T3 (da)
ES (1) ES2090244T3 (da)
GR (1) GR3021703T3 (da)
HU (1) HU212102B (da)
IE (1) IE77637B1 (da)
NZ (1) NZ237929A (da)
PT (1) PT97660B (da)
ZA (1) ZA913509B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
DE4402379C2 (de) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
EP2253327A1 (en) * 1996-04-05 2010-11-24 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
EP1514543A1 (en) 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6172441B1 (en) 1999-06-28 2001-01-09 Visteon Global Technologies, Inc. Rotor assembly
BR0013704A (pt) 1999-08-30 2002-05-07 Aventis Pharma Gmbh Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2274013T3 (es) 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US20040137054A1 (en) * 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004085448A2 (en) * 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit

Also Published As

Publication number Publication date
DE69121464D1 (de) 1996-09-26
HU911620D0 (en) 1991-11-28
EP0457514A1 (en) 1991-11-21
KR910019614A (ko) 1991-12-19
CA2040865C (en) 2002-07-23
IE77637B1 (en) 1997-12-31
CA2040865A1 (en) 1991-11-16
ES2090244T3 (es) 1996-10-16
EP0457514B1 (en) 1996-08-21
KR100200467B1 (ko) 1999-06-15
AU651579B2 (en) 1994-07-28
GR3021703T3 (en) 1997-02-28
PT97660B (pt) 1998-09-30
HU212102B (en) 1996-02-28
AU7627091A (en) 1991-11-21
PT97660A (pt) 1992-02-28
DE69121464T2 (de) 1997-03-27
ZA913509B (en) 1992-02-26
NZ237929A (en) 1997-06-24
ATE141514T1 (de) 1996-09-15
IE911431A1 (en) 1991-11-20
JPH04226921A (ja) 1992-08-17
HUT57993A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
DK0457514T3 (da) Fremgangsmåde til forebyggelse, stabilisering eller fremkaldelse af tilbagegang af atherosklerose ved anvendelse af en kombination af et cholesterolsænkende medikament og en ACE-hæmmer
DK0738512T3 (da) Fremgangsmåde til forebyggelse af et andet hjerteanfald ved anvendelse af en HMG coenzsym A reduktasehæmmer
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
TW256839B (en) Process of preventing (methyl) acrylic acid and its ester from polymerization
DK1140184T3 (da) Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
DK370486D0 (da) Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf
DK162488D0 (da) Middel til behandling af hyperchlolesterolaemi
DE69306808D1 (de) Hilfs- oder ergänzungsorthese des knies
DK0428302T3 (da) Enzymatisk spaltning af endo-bicyclo(2.2.1)heptan-2-o1 og afledte farmaceutiske midler
DE69306915D1 (de) Kombination zur Detektion von Weichgewebeanomalien
EP0684951A1 (en) SILYL ACETYLCHOLINESTERASE INHIBITORS.
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
DK485888A (da) Hmg-coa reduktaseinhibitor og fremgangsmaade til fremstilling deraf
DE59107262D1 (de) Oxetanone
DK0586518T3 (da) Cholesterolnedsættende tocopherolanaloge
NO920546D0 (no) Fremgangsmaate ved fluksing og fluksholdige komponenter
FI950696A7 (fi) Menetelmä HIV:n replikaation estämiseksi IL-4:ää käyttämällä
DK486088D0 (da) Hmg-coa reduktaseinhibitor og fremgangsmaade til fremstilling deraf
KR970006087U (ko) 보조서랍이 부설된 탁상금고
NO913801D0 (no) Fremgangsmaate ved enkelthud-bygging av fartoey.
KR950015818U (ko) 고조파 제거용 안정화 증폭회로
DK109693D0 (da) Fremgangsmaade og anlaeg til omsaetning af biomasse ved hjaelp af mikroorganismer
NO893070D0 (no) Fremgangsmaate ved solubilisering.
KR950002644U (ko) 골절기의 안전밀대
NO944055D0 (no) Overflatesterilisering ved laserbehandling